Sacituzumab tirumotecan for thymic carcinoma after chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new drug called sacituzumab tirumotecan for people with thymic carcinoma that has spread or come back after platinum-based chemotherapy. The drug targets a protein on cancer cells to deliver chemotherapy directly to them, which may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with thymic carcinoma that has spread (stage IV), is stage III and cannot be removed with surgery, or has come back after surgery.
- You are 18 years or older and are able to take care of yourself (ECOG performance status 0 or 1).
- You have already received at least one line of chemotherapy that included a platinum drug (like cisplatin or carboplatin).
- You have not had certain other cancer drugs or treatments within the last 4 weeks, and no strong CYP3A4 inducers/inhibitors.
- Your blood counts, liver, and kidney functions are within required limits, and your oxygen level is 92% or higher.
- You do not have uncontrolled brain metastases, severe heart problems, active infections, or a history of interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cancer drug called sacituzumab tirumotecan (a targeted antibody-drug) in patients with adenoid cystic carcinoma or papillary thyroid cancer that has spread or cannot be surgically removed. The drug is designed to find and attack cancer cells while minimizing harm to healthy cells.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a new drug, sacituzumab tirumotecan, in people with squamous cell carcinoma of the anus or rectum that has spread or cannot be removed. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Hear when a new Unresectable Thymic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.